Skip to main content
NEXTURNBIOSCIENCE Co., LTD logo

NEXTURNBIOSCIENCE Co., LTD — Investor Relations & Filings

Ticker · 089140 ISIN · KR7089140008 KO Professional, scientific and technical activities
Open in API
Filings indexed 486 across all filing types
Latest filing 2024-10-07 Major Shareholding Noti…
Country KR South Korea
Listing KO 089140

About NEXTURNBIOSCIENCE Co., LTD

http://www.nexturn.co.kr

NEXTURNBIOSCIENCE Co., LTD. is a specialized manufacturer of Computer Numerical Control (CNC) automatic lathes, with a focus on Swiss-type models. The company develops and produces a range of machines, including both guide bush and non-guide bush types, utilizing proprietary technology. In addition to its core machinery business, NEXTURNBIOSCIENCE leverages its expertise in ultra-precision manufacturing to produce essential functional components. These high-quality parts serve critical applications across diverse sectors, including information technology (IT), construction equipment, and the medical industry, reflecting the company's expanding business scope.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the acquisition of convertible bonds (CB) by CMG Pharmaceutical in Nexturn Bioscience. This type of filing is a mandatory regulatory disclosure regarding significant ownership changes and does not fit into other specific categories like M&A or Director's Dealing, making 'RNS' (Regulatory Filings) the most appropriate classification.
2024-10-07 Korean
전환가액의조정
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from a Korean company (Nexturn Bio) regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure is a standard regulatory requirement for listed companies in Korea to inform shareholders of changes in capital structure and potential dilution. It falls under the category of 'Regulatory Filings' (RNS) as it is a specific corporate disclosure that does not fit into the other specialized categories like M&A, dividends, or director dealings.
2024-09-19 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) regarding the adjustment of the conversion price for convertible bonds (CB). It details the change in conversion price, the number of convertible shares, and the underlying rationale (market price fluctuations). This type of corporate action directly impacts the company's capital structure and financing terms, falling under the 'Capital/Financing Update' category.
2024-09-09 Korean
전환가액의조정
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing from a Korean company (Nexturn Bio) regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure is a standard corporate action related to capital structure and financing instruments. Since it does not fit into specific categories like M&A, dividends, or director dealings, and is a direct regulatory disclosure of a financial event, it is classified as a Regulatory Filing (RNS).
2024-08-19 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for Nexturn Bioscience, covering the period from January 1, 2024, to June 30, 2024. It contains detailed corporate information, financial data, management discussions, and governance details. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial and operational data for a period shorter than a full fiscal year. H1 2024
2024-08-14 Korean
전환가액의조정
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) regarding the adjustment of the conversion price (Refixing) for convertible bonds issued by Nexturn Bio. This type of filing, which details changes to capital structure instruments like convertible bonds, falls under the 'Capital/Financing Update' category as it directly relates to financing activities and capital structure modifications.
2024-08-07 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.